Marnix Jansen1, Dirk W Schölvinck2, Ryoji Kushima3, Shigeki Sekine3, Bas L A M Weusten4, Guiqi Q Wang5, David E Fleischer6, Shigetaka Yoshinaga7, Sanford M Dawsey8, Sybren L Meijer1, Jacques J G H M Bergman9, Ichiro Oda7. 1. Department of Pathology, Academic Medical Center, Amsterdam, the Netherlands. 2. Department of Gastroenterology and Hepatology, Academic Medical Center, Amsterdam, the Netherlands; Department of Gastroenterology and Hepatology, St. Antonius Hospital, Nieuwegein, the Netherlands. 3. Pathology Division, National Cancer Center Hospital, Tokyo, Japan. 4. Department of Gastroenterology and Hepatology, St. Antonius Hospital, Nieuwegein, the Netherlands. 5. Department of Endoscopy, Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China. 6. Department of Gastroenterology and Hepatology, Mayo Clinic, Scottsdale, Arizona, USA. 7. Endoscopy Division, National Cancer Center Hospital, Tokyo, Japan. 8. Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA. 9. Department of Gastroenterology and Hepatology, Academic Medical Center, Amsterdam, the Netherlands.
Abstract
BACKGROUND: Endoscopic radiofrequency ablation (RFA) appears to be a safe and effective treatment for flat-type noninvasive squamous neoplasia of the esophagus. However, if RFA is applied to lesions containing invasive cancer (esophageal squamous cell carcinoma [ESCC]), histological features associated with lymph node metastases may remain undetected. In addition, extension of neoplasia down the ducts of esophageal submucosal glands (SMGs) may create a sheltered "niche" beyond the reach of ablation. OBJECTIVE: To determine the RFA eligibility of flat-type ESCC. DESIGN: Retrospective analysis of prospectively collected data of ESCC patients. SETTING: National Cancer Center Hospital, Tokyo, Japan. PATIENTS: Patients with flat-type ESCC larger than 3 cm removed by endoscopic submucosal dissection (ESD). INTERVENTIONS: Three endoscopists involved in RFA studies in China reviewed endoscopic images to select lesions eligible for RFA. Corresponding ESD resection specimens were histologically examined. MAIN OUTCOME MEASUREMENTS: The presence of poor histological features (ie, invasion in m3 or deeper, poor tumor differentiation, or lymphovascular invasion) and the number of involved esophageal SMGs and ducts. RESULTS: Sixty-five lesions were included, 17 (26%) of which qualified as RFA eligible by RFA endoscopists. Interobserver agreement for this assessment was poor (κ = 0.09). Six of the 17 specimens (35%) showed relevant disease: 4 lesions invaded in the muscularis mucosae, 1 of which also showed lymphovascular invasion; 2 lesions showed extension of neoplasia into SMGs. LIMITATIONS: Limited number of cases. RFA eligibility status was based on analysis of still images. CONCLUSIONS: One third of flat-type ESCC, deemed eligible for RFA, demonstrated histological features that are considered (relative) contraindications to endoscopic treatment. Because it appears difficult for endoscopists to identify low-risk ESCC, conservative use of RFA for flat-type ESCC is advocated until long-term follow-up data are available.
BACKGROUND: Endoscopic radiofrequency ablation (RFA) appears to be a safe and effective treatment for flat-type noninvasive squamous neoplasia of the esophagus. However, if RFA is applied to lesions containing invasive cancer (esophageal squamous cell carcinoma [ESCC]), histological features associated with lymph node metastases may remain undetected. In addition, extension of neoplasia down the ducts of esophageal submucosal glands (SMGs) may create a sheltered "niche" beyond the reach of ablation. OBJECTIVE: To determine the RFA eligibility of flat-type ESCC. DESIGN: Retrospective analysis of prospectively collected data of ESCC patients. SETTING: National Cancer Center Hospital, Tokyo, Japan. PATIENTS: Patients with flat-type ESCC larger than 3 cm removed by endoscopic submucosal dissection (ESD). INTERVENTIONS: Three endoscopists involved in RFA studies in China reviewed endoscopic images to select lesions eligible for RFA. Corresponding ESD resection specimens were histologically examined. MAIN OUTCOME MEASUREMENTS: The presence of poor histological features (ie, invasion in m3 or deeper, poor tumor differentiation, or lymphovascular invasion) and the number of involved esophageal SMGs and ducts. RESULTS: Sixty-five lesions were included, 17 (26%) of which qualified as RFA eligible by RFA endoscopists. Interobserver agreement for this assessment was poor (κ = 0.09). Six of the 17 specimens (35%) showed relevant disease: 4 lesions invaded in the muscularis mucosae, 1 of which also showed lymphovascular invasion; 2 lesions showed extension of neoplasia into SMGs. LIMITATIONS: Limited number of cases. RFA eligibility status was based on analysis of still images. CONCLUSIONS: One third of flat-type ESCC, deemed eligible for RFA, demonstrated histological features that are considered (relative) contraindications to endoscopic treatment. Because it appears difficult for endoscopists to identify low-risk ESCC, conservative use of RFA for flat-type ESCC is advocated until long-term follow-up data are available.
Authors: Jacques J G H M Bergman; Yue-Ming Zhang; Shun He; Bas Weusten; Liyan Xue; David E Fleischer; Ning Lu; Sanford M Dawsey; Gui-Qi Wang Journal: Gastrointest Endosc Date: 2011-08-15 Impact factor: 9.427
Authors: Roos E Pouw; Katja Wirths; Pierre Eisendrath; Carine M Sondermeijer; Fiebo J Ten Kate; Paul Fockens; Jacques Devière; Horst Neuhaus; Jacques J Bergman Journal: Clin Gastroenterol Hepatol Date: 2009-08-11 Impact factor: 11.382
Authors: Nicholas J Shaheen; Prateek Sharma; Bergein F Overholt; Herbert C Wolfsen; Richard E Sampliner; Kenneth K Wang; Joseph A Galanko; Mary P Bronner; John R Goldblum; Ana E Bennett; Blair A Jobe; Glenn M Eisen; M Brian Fennerty; John G Hunter; David E Fleischer; Virender K Sharma; Robert H Hawes; Brenda J Hoffman; Richard I Rothstein; Stuart R Gordon; Hiroshi Mashimo; Kenneth J Chang; V Raman Muthusamy; Steven A Edmundowicz; Stuart J Spechler; Ali A Siddiqui; Rhonda F Souza; Anthony Infantolino; Gary W Falk; Michael B Kimmey; Ryan D Madanick; Amitabh Chak; Charles J Lightdale Journal: N Engl J Med Date: 2009-05-28 Impact factor: 91.245
Authors: Aymeric Becq; Marine Camus; Gabriel Rahmi; Vincent de Parades; Philippe Marteau; Xavier Dray Journal: United European Gastroenterol J Date: 2015-08 Impact factor: 4.623
Authors: Yan Ke; Sanne N van Munster; Liyan Xue; Shun He; Yueming Zhang; Lizhou Dou; Yong Liu; Xudong Liu; Yumeng Liu; Wei Li; Ning Lv; Sanford M Dawsey; Bas L A M Weusten; Jacques J G H M Bergman; Guiqi Wang Journal: Gastrointest Endosc Date: 2019-03-25 Impact factor: 9.427
Authors: Xinying Yu; Sanne N van Munster; Yueming Zhang; Liyan Xue; David E Fleischer; Bas L A M Weusten; Ning Lu; Sanford S M Dawsey; Jacques J G H M Bergman; Guiqi Wang Journal: Gastrointest Endosc Date: 2018-10-26 Impact factor: 9.427